|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM182417069 |
| 003 |
DE-627 |
| 005 |
20231223162841.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231223s2008 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2008.08.001
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0608.xml
|
| 035 |
|
|
|a (DE-627)NLM182417069
|
| 035 |
|
|
|a (NLM)18790672
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Lu, Ming-Chi
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Nifedipine suppresses Th1/Th2 cytokine production and increased apoptosis of anti-CD3 + anti-CD28-activated mononuclear cells from patients with systemic lupus erythematosus via calcineurin pathway
|
| 264 |
|
1 |
|c 2008
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 04.12.2008
|
| 500 |
|
|
|a Date Revised 16.11.2017
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Increased Ca(2+) influx is found in mononuclear cells (MNC) of patients with systemic lupus erythematosus (SLE). The role of calcineurin and potential implication of calcium channel blocker to suppress the abnormal Ca(2+) influx in SLE remain to be determined. In the present study, we found that the expression and phosphatase activity of calcineurin, but not calcineurin inhibitor in SLE-MNC were greater than normal MNC. Functionally, 1 microM nifedipine could suppress SLE-MNC IFN-gamma secretion but 10 microM nifedipine was required for suppressing that of normal MNC. IL-10 secretion by both SLE-MNC and normal MNC was suppressed by 1 microM nifedipine. However, high dose of nifedipine (50 microM) suppressed NFATc1 activation in SLE-MNC and enhanced apoptosis of anti-CD3 + anti-CD28-activated SLE-MNC irrelevant to expression of Fas ligand. These data suggest that SLE-MNC overexpressed calcineurin and hyper-responded to L-type Ca(2+) channel blocker-mediated apoptosis and cytokine suppression. We proposed that L-type Ca(2+) channel blocker maybe a potential medication for controlling SLE
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Adaptor Proteins, Signal Transducing
|2 NLM
|
| 650 |
|
7 |
|a CABIN1 protein, human
|2 NLM
|
| 650 |
|
7 |
|a CD28 Antigens
|2 NLM
|
| 650 |
|
7 |
|a CD3 Complex
|2 NLM
|
| 650 |
|
7 |
|a Calcium Channel Blockers
|2 NLM
|
| 650 |
|
7 |
|a Calcium Channels, L-Type
|2 NLM
|
| 650 |
|
7 |
|a Cytokines
|2 NLM
|
| 650 |
|
7 |
|a FASLG protein, human
|2 NLM
|
| 650 |
|
7 |
|a Fas Ligand Protein
|2 NLM
|
| 650 |
|
7 |
|a NFATC Transcription Factors
|2 NLM
|
| 650 |
|
7 |
|a NFATC1 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-10
|2 NLM
|
| 650 |
|
7 |
|a 130068-27-8
|2 NLM
|
| 650 |
|
7 |
|a Interferon-gamma
|2 NLM
|
| 650 |
|
7 |
|a 82115-62-6
|2 NLM
|
| 650 |
|
7 |
|a Calcineurin
|2 NLM
|
| 650 |
|
7 |
|a EC 3.1.3.16
|2 NLM
|
| 650 |
|
7 |
|a Phosphoric Monoester Hydrolases
|2 NLM
|
| 650 |
|
7 |
|a EC 3.1.3.2
|2 NLM
|
| 650 |
|
7 |
|a Nifedipine
|2 NLM
|
| 650 |
|
7 |
|a I9ZF7L6G2L
|2 NLM
|
| 700 |
1 |
|
|a Lai, Ning-Sheng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yu, Hui-Chun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hsieh, Song-Chou
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tung, Chien-Hsueh
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yu, Chia-Li
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 129(2008), 3 vom: 10. Dez., Seite 462-70
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:129
|g year:2008
|g number:3
|g day:10
|g month:12
|g pages:462-70
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2008.08.001
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 129
|j 2008
|e 3
|b 10
|c 12
|h 462-70
|